Pitout J D, Thomson K S, Hanson N D, Ehrhardt A F, Moland E S, Sanders C C
Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, Nebraska 68178, USA.
Antimicrob Agents Chemother. 1998 Jun;42(6):1350-4. doi: 10.1128/AAC.42.6.1350.
Although resistance to the expanded-spectrum cephalosporins among members of the family Enterobacteriaceae lacking inducible beta-lactamases occurs virtually worldwide, little is known about this problem among isolates recovered in South Africa. Isolates of Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis resistant to expanded-spectrum cephalosporins recovered from patients in various parts of South Africa over a 3-month period were investigated for extended-spectrum beta-lactamase production. Antibiotic susceptibility was determined by standard disk diffusion and agar dilution procedures. Production of extended-spectrum beta-lactamases was evaluated by using the double-disk test, and the beta-lactamases were characterized by spectrophotometric hydrolysis assays and an isoelectric focusing overlay technique which simultaneously determined isoelectric points and general substrate or inhibitor characteristics. DNA amplification and sequencing were performed to confirm the identities of these enzymes. The P. mirabilis and E. coli isolates were found to produce TEM-26-type, SHV-2, and SHV-5 extended-spectrum beta-lactamases. An AmpC-related enzyme which had a pI of 8.0 and which conferred resistance to cefoxitin as well as the expanded-spectrum cephalosporins was found in a strain of K. pneumoniae. This is the first study which has identified organisms producing different extended-spectrum beta-lactamases from South Africa and the first report describing strains of P. mirabilis producing a TEM-26-type enzyme. The variety of extended-spectrum beta-lactamases found among members of the family Enterobacteriaceae isolated from major medical centers in South Africa is troubling and adds to the growing list of countries where these enzymes pose a serious problem for antimicrobial therapy.
尽管在缺乏诱导型β-内酰胺酶的肠杆菌科成员中,对广谱头孢菌素的耐药性几乎在全球范围内都有发生,但对于在南非分离出的菌株中这个问题却知之甚少。对在3个月期间从南非各地患者中分离出的对广谱头孢菌素耐药的肺炎克雷伯菌、大肠埃希菌和奇异变形杆菌菌株进行了超广谱β-内酰胺酶产生情况的调查。通过标准纸片扩散法和琼脂稀释法测定抗生素敏感性。采用双纸片试验评估超广谱β-内酰胺酶的产生情况,并通过分光光度水解试验和等电聚焦覆盖技术对β-内酰胺酶进行表征,该技术可同时确定等电点以及一般底物或抑制剂特征。进行DNA扩增和测序以确认这些酶的身份。发现奇异变形杆菌和大肠埃希菌分离株产生TEM-26型、SHV-2和SHV-5超广谱β-内酰胺酶。在一株肺炎克雷伯菌中发现了一种与AmpC相关的酶,其pI为8.0,对头孢西丁以及广谱头孢菌素具有耐药性。这是第一项鉴定出南非产生不同超广谱β-内酰胺酶的微生物的研究,也是第一份描述产生TEM-26型酶的奇异变形杆菌菌株的报告。在从南非主要医疗中心分离出的肠杆菌科成员中发现的多种超广谱β-内酰胺酶令人担忧,这也增加了这些酶对抗菌治疗构成严重问题的国家名单。